Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease. (June 2017)

• Record Type: Journal Article
• Authors: Kanaji, Nobuhiro; Sakai, Kenichiro; Ueda, Yutaka; Miyawaki, Hiroshi; Ishii, Tomoya; Watanabe, Naoki; Kita, Nobuyuki; Kadota, Kyuichi; Kadowaki, Norimitsu; Bandoh, Shuji
• Is Part Of: Lung cancer. Volume 108(2017)
• Page Start: 126
• Page End: 133
• Publication Date: 2017-06
• Subjects: SCLC small cell lung cancer -- ILD interstitial lung disease -- NSCLC non-small cell lung cancer -- TTF-1 thyroid transcription factor-1 -- UIP usual interstitial pneumonia -- AE acute exacerbation -- PFS progression-free survival -- OS overall survival -- PS performance status; Location -- Peripheral -- Central -- Small cell lung cancer -- Interstitial lung disease -- Prognosis; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2017.03.013
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Peripheral-type is more common than central-type in small cell lung cancer. Peripheral-type is an independent better prognostic factor for overall survival. Peripheral-type is associated with higher frequency of interstitial lung disease. Interstitial lung disease is associated with shorter survival. Survival in peripheral-type without interstitial lung disease is much longer. Abstract: Objectives: Small cell lung cancer (SCLC) can be subgrouped into central and peripheral types according to the location of the primary lesion. However, the clinical differences between these two types remain unclear. This study compared their clinical features. Materials and methods: Data on 231 patients with pathologically diagnosed SCLC were retrospectively subgrouped into central or peripheral types. Progression-free survival (PFS), overall survival (OS), treatments, responses to first-line therapy, and frequency of interstitial lung disease (ILD) were compared between the two groups. Results: Of the 231 patients, 101 (44%) had central-type and 130 (56%) had peripheral-type SCLC. Peripheral-type SCLC was associated with a better performance status, higher frequency of ILD, and higher rate of limited disease stage. Patients with peripheral-type SCLC had a significantly longer OS than did those with central-type SCLC (median, 502 vs 370 days, respectively; p = 0.0186). Tumor location was not associated with PFS. PFS was poorer in patients with than without ILD (median, 143 vs 213 days, respectively; p = 0.0038), as was OS (median, 245 vs 545 days, respectively; p = 0.0014). Among patients without ILD, OS was longer in those with peripheral- than central-type tumors (median, 662 vs 421 days, respectively; p = 0.0074). Surgical resection was more often chosen for peripheral-type tumors, and this was one reason for the prolonged survival. There was no difference in the response to chemotherapy and/or radiotherapy between central- and peripheral-type SCLC. Multivariate analysis by a Cox proportional hazards model showed that male sex, a poor performance status, extensive disease, the presence of ILD, an elevated serum neuron-specific enolase concentration, and central-type SCLC were poor prognostic factors for OS. Conclusion: Peripheral-type SCLC is associated with better OS and a higher frequency of ILD than is central-type SCLC. The presence of ILD is a poor prognostic factor for both PFS and OS.